Loading news...
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
111 Capital grew its stake in shares of DexCom, Inc. (NASDAQ: DXCM) by 62.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,004 shares of the medical device company's stock after purchasing an additional 10,040 shares during the quarter. 111
Andra AP fonden raised its position in DexCom, Inc. (NASDAQ: DXCM) by 30,833.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 92,800 shares of the medical device company's stock after buying an additional 92,500 shares during the period.
DNB Asset Management AS raised its holdings in shares of DexCom, Inc. (NASDAQ: DXCM) by 271.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,098,544 shares of the medical device company's stock after acquiring an additional 803,086 shares during the quarter.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Rick Osterloh to Board of Directors.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders.
Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live presentation is scheduled to begin at approximately 1:05 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. D.
Raiffeisen Bank International AG decreased its stake in DexCom, Inc. (NASDAQ: DXCM) by 37.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,223 shares of the medical device company's stock after selling 9,076 shares during the
Aurora Investment Counsel purchased a new stake in DexCom, Inc. (NASDAQ: DXCM) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 33,994 shares of the medical device company's stock, valued at approximately $2,287,000. A number of other institutional investors have also added
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dan Deming sees the rotation trade continuing if markets can hold recent momentum this trading week. As for the Big 3, he sees a breakout candidate in Verizon (VZ), DexCom's (DXCM) potential to continue its recent upside momentum, and Applied Materials (AMAT) serving as a rising giant in the semiconductor trade.
NEOS Investment Management LLC grew its holdings in shares of DexCom, Inc. (NASDAQ: DXCM) by 58.7% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 175,982 shares of the medical device company's stock after buying an additional 65,066 shares during
Brooktree Capital Management increased its stake in DexCom, Inc. (NASDAQ: DXCM) by 43.2% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 41,880 shares of the medical device company's stock after purchasing an additional 12,635 shares during the quarter. DexCom makes up 1.8%
Senator John Boozman (R-Arkansas) recently sold shares of Union Pacific Corporation (NYSE: UNP). In a filing disclosed on February 15th, the Senator disclosed that they had sold between $1,001 and $15,000 in Union Pacific stock on January 29th. Senator John Boozman also recently made the following trade(s): Sold $1,001 - $15,000 in shares of Omnicom Group
Senator John Boozman (R-Arkansas) recently sold shares of Micron Technology, Inc. (NASDAQ: MU). In a filing disclosed on February 15th, the Senator disclosed that they had sold between $1,001 and $15,000 in Micron Technology stock on January 26th. Senator John Boozman also recently made the following trade(s): Sold $1,001 - $15,000 in shares of Omnicom Group
Senator John Boozman (R-Arkansas) recently sold shares of abrdn Physical Platinum Shares ETF (NYSEARCA:PPLT). In a filing disclosed on February 15th, the Senator disclosed that they had sold between $1,001 and $15,000 in abrdn Physical Platinum Shares ETF stock on January 23rd. Senator John Boozman also recently made the following trade(s): Sold $1,001 - $15,000
Senator John Boozman (R-Arkansas) recently bought shares of Janus Henderson Mortgage-Backed Securities ETF (NYSEARCA:JMBS). In a filing disclosed on February 15th, the Senator disclosed that they had bought between $1,001 and $15,000 in Janus Henderson Mortgage-Backed Securities ETF stock on January 23rd. Senator John Boozman also recently made the following trade(s): Sold $1,001 - $15,000
Senator John Boozman (R-Arkansas) recently sold shares of iShares Russell 2000 ETF (NYSEARCA:IWM). In a filing disclosed on February 15th, the Senator disclosed that they had sold between $1,001 and $15,000 in iShares Russell 2000 ETF stock on January 23rd. Senator John Boozman also recently made the following trade(s): Sold $1,001 - $15,000 in shares
Senator John Boozman (R-Arkansas) recently bought shares of CVS Health Corporation (NYSE: CVS). In a filing disclosed on February 15th, the Senator disclosed that they had bought between $1,001 and $15,000 in CVS Health stock on January 29th. Senator John Boozman also recently made the following trade(s): Sold $1,001 - $15,000 in shares of Omnicom Group